In research presented at the ACR Convergence 2021, investigators estimated the risk of major adverse cardiac events in patients with systemic lupus erythematosus undergoing moderate-risk to high-risk surgery.
A team of investigators assessed the speed with which patients with systemic lupus erythematosus decreased their use of glucocorticoids following treatment with belimumab vs placebo.
Researchers compared the clinical manifestation of patients with systemic lupus erythematosus with the anti-gAChR antibody.
Researchers assessed the prevalence of SLE among patients with vs without myasthenia gravis (MG), and studied the demographics of patients with MG who developed SLE after their MG diagnosis.
Researchers used pooled data from the TULIP-1 and TULIP-2 trials to assess the effect of prior biologics use on anifrolumab efficacy and safety in systemic lupus erythematosus.
Researchers assessed the predictors of remission and lupus low disease activity state (LLDAS) in patients with systemic lupus erythematosus.
Researchers studied the association between functional connectivity, permeability of the blood-brain barrier, and cognitive impairment in patients with systemic lupus erythematosus.
Researchers analyzed mortality trends in lupus nephritis in the US from 1999 to 2019 and identified population characteristics associated with mortality.
Researchers assessed the association between disease activity status and SLE flare risk after hydroxychloroquine reduction or discontinuation vs maintenance.
In a second interim analysis of the AURORA 2 extension study, researchers reported on the effects of voclosporin on lupus nephritis.